The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents.

The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.

Methods of preferentially enhancing in a subject an antibody-dependent cell-mediated cytotoxicity (ADCC) antibody response over a neutralizing antibody response to a vaccine for an infectious agent using herpesvirus entry mediator (HVEM) agonists, and related compositions.

The present disclosure provides a method to prepare purified enveloped viral particle preparations employing ion exchange chromatography and tangential flow filtration.

The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.

The present invention relates to compositions comprising HSV antigens and methods for their use in the treatment or prevention of asymptomatic and symptomatic herpesvirus infection, or recurrence.

This invention pertains to the identification of antibody mediated epitope mimics and applications of the identification of said mimic peptides in the design of biotherapeutics and vaccines.

The present disclosure relates to compositions and methods for treating or preventing neonatal herpes simplex virus (HSV) infection and/or the neurological and/or non-neurological sequelae thereof.

The present invention refers to a vector system, usable as a platform vector and suitable for the production of transgenic viruses of the subfamily Alphaherpesvirinae. Such transgenic viruses can be used as vaccine or as oncolytic virus or in gene therapy. The platform vector of the present invention is a vector system allowing a simplified search for and generation and production of viruses with a modified and increased functionality. The present invention refers also to the use of the platform vector as a vector system for the generation and the production of transgenic viruses, methods for the production of a transgenic virus, using the vector system of the present invention and viruses obtained by such methods.

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, compositions and vaccines comprising such, and methods of use thereof are each provided.